Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins

Clinical and Vaccine Immunology

Volumn 20, Issue 2, 2013, Pages 205-210

  Polack, Fernando P ^a,b,e   Lydy, Shari L ^c,f   Lee, Sok Hyong ^a,g   Rota, Paul A ^d   Bellini, William J ^d   Adams, Robert J ^b   Robinson, Harriet L ^c,h   Griffin, Diane E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; MEASLES VACCINE; NEUTRALIZING ANTIBODY; VIRUS FUSION PROTEIN; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; MEASLES; MEASLES VACCINATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RHESUS MONKEY; VIREMIA; VIRUS IMMUNITY; VIRUS STRAIN; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEMAGGLUTININS, VIRAL; IMMUNOGLOBULIN G; MACACA MULATTA; MEASLES; MEASLES VACCINE; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, ATTENUATED; VACCINES, DNA; VIRAL FUSION PROTEINS;

EID: 84874921452     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00394-12     Document Type: Article

References (49)

1. Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. 2009. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int. J. Epidemiol. 38:192-205.
2. Centers for Disease Control and Prevention. 2009. Global measles mortality, 2000-2008. Morb. Mort. Wkly. Rep. 58:1321-1326.
3. Nandy R, Handzel T, Zaneidou M, Biey J, Coddy RZ, Perry R, Strebel P, Cairns L. 2006. Case-fatality rate during a measles outbreak in eastern Niger in 2003. Clin. Infect. Dis. 42:322-328.
4. Moss WJ, Griffin DE. 2012. Measles. Lancet 379:153-164.
5. Centers for Disease Control and Prevention. 2012. Measles-United States, 2011. Morb. Mortal. Wkly. Rep. 61:253-258.
6. Centers for Disease Control and Prevention. 2012. Progress in global measles control, 2000-2010. Morb. Mortal. Wkly. Rep. 61:73-78.
7. Sanchez-Schmitz G, Levy O. 2011. Development of newborn and infant vaccines. Sci. Transl. Med. 3:90ps27. doi:10.1126/scitranslmed.3001880.
8. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715-718.
9. Holt EA, Moulton LH, Siberry GK, Halsey NA. 1993. Differential mortality by measles vaccine titer and sex. J. Infect. Dis. 168:1087-1096.
10. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. 1998. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527-532.
11. Gans HA, Maldonado Y, Yasukawa LL, Beeler J, Audet S, Rinki MM, DeHovitz R, Arvin AM. 1999. IL-12, IFN-γ, and T cell proliferation to measles in immunized infants. J. Immunol. 162:5569-5575.
12. Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE. 2007. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J. Infect. Dis. 196:1339-1345.
13. Garenne M, Leroy O, Beau J-P, Sene I. 1991. Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 338: 903-907.
14. Aaby P, Andersen M, Knudsen K. 1993. Excess mortality after early exposure to measles. Int. J. Epidemiol. 22:156-162.
15. Auwaerter PG, Rota PA, Elkins WR, Adams RJ, DeLozier T, Shi Y, Bellini WJ, Murphy BR, Griffin DE. 1999. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J. Infect. Dis. 180:950-958.
16. El Mubarak HS, Yuksel S, van Amerongen G, Mulder PG, Mukhtar MM, Osterhaus AD, de Swart RL. 2007. Infection of cynomolgus macaques (Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type measles viruses. J. Gen. Virol. 88:2028-2034.
17. Van Binnendijk RS, van der Heijden RWJ, van Amerongen G, Uytdehaag FGCM, Osterhaus ADME. 1994. Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J. Infect. Dis. 170:443-448.
18. Zhu Y, Heath J, Collins J, Greene T, Antipa L, Rota P, Bellini W, McChesney M. 1997. Experimental measles: infection and immunity in the rhesus macaque. Virology 233:85-92.
19. McChesney MB, Miller CJ, Rota PA, Zhu Y, Antipa L, Lerche NW, Ahmed R, Bellini WJ. 1997. Experimental measles. 1. Pathogenesis in the normal and the immunized host. Virology 233:74-84.
20. Kato SI, Nagata K, Takeuchi K. 2012. Cell tropism and pathogenesis of measles virus in monkeys. Front. Microbiol. 3:14. doi:10.3389/fmicb.2012 .00014.
21. de Vries RD, Stittelaar KJ, Osterhaus AD, de Swart RL. 2008. Measles vaccination: new strategies and formulations. Expert Rev. Vaccines 7:1215-1223.
22. Griffin DE, Pan C-H. 2009. Measles: old vaccines, new vaccines. Curr. Top. Microbiol. Immunol. 330:191-212.
23. Stittelaar KJ, de Swart RL, Vos HW, van Amerongen G, Sixt N, Wild TF, Osterhaus AD. 2002. Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination. Vaccine 20:2022-2026.
24. Polack F, Lee S, Permar S, Manyara E, Nousari H, Jeng Y, Mustafa F, Valsamakis A, Adams R, Robinson H, Griffin D. 2000. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med. 6:776-781.
25. Polack FP, Hoffman SJ, Moss WJ, Griffin DE. 2003. Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge. J. Infect. Dis. 187:1794-1800.
26. Premenko-Lanier M, Rota P, Rhodes G, Bellini W, McChesney M. 2004. PriorDNAvaccination does not interfere with the live-attenuated measles vaccine. Vaccine 22:762-765.
27. Pan CH, Nair N, Adams RJ, Zink MC, Lee EY, Polack FP, Singh M, O'Hagan DT, Griffin DE. 2008. Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin. Vaccine Immunol. 15:697-706.
28. Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Griffin DE. 2008. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin. Vaccine Immunol. 15:1214-1221.
29. Pasetti MF, Resendiz-Albor A, Ramirez K, Stout R, Papania M, Adams RJ, Polack FP, Ward BJ, Burt D, Chabot S, Ulmer J, Barry EM, Levine MM. 2007. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin. Pharmacol. Ther. 82:672-685.
30. Kodihalli S, Haynes JR, Robinson HL, Webster RG. 1997. Crossprotection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J. Virol. 71:3391-3396.
31. Kobune F, Sakata H, Sugiura A. 1990. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J. Virol. 64:700-705.
32. Polack FP, Auwaerter PG, Lee S-H, Nousari HC, Valsamakis A, Leiferman KM, Diwan A, Adams RJ, Griffin DE. 1999. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusioninhibiting antibody. Nat. Med. 5:629-634.
33. Cohen BJ, Audet S, Andrews N, Beeler J. 2007. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 26:59-66.
34. Jacobson S, Richert JR, Biddison WE, Satinsky A, Hartzman RJ, Mc-Farland HF. 1984. Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J. Immunol. 133:754-757.
35. Jaye A, Magnusen AF, Sadiq AD, Corrrah T, Whittle HC. 1998. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children. J. Clin. Investig. 102:1969-1977.
36. Jaye A, Magnusen AF, Whittle HC. 1998. Human leukocyte antigen class I- and class II-restricted cytotoxic T lymphocyte responses to measles antigens in immune adults. J. Infect. Dis. 177:1282-1289.
37. Hodgins DC, Shewen PE. 2012. Vaccination of neonates: problem and issues. Vaccine 30:1541-1559.
38. Premenko-Lanier M, Rota PA, Rhodes G, Verhoeven D, Barouch DH, Lerche NW, Letvin NL, Bellini WJ, McChesney MB. 2003. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology 307:67-75.
39. Premenko-Lanier M, Rota PA, Rhodes GH, Bellini WJ, McChesney MB. 2004. Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J. Infect. Dis. 189:2064-2071.
40. Siegrist CA, Aspinall R. 2009. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9:185-194.
41. Makori N, Tarantal AF, Lu FX, Rourke T, Marthas ML, McChesney MB, Hendrickx AG, Miller CJ. 2003. Functional and morphological development of lymphoid tissues and immune regulatory and effector function in rhesus monkeys: cytokine-secreting cells, immunoglobulinsecreting cells, and CD5(+) B-1 cells appear early in fetal development. Clin. Diagn. Lab. Immunol. 10:140-153.
42. Zhu Y, Rota P, Wyatt L, Tamin A, Rozenblatt S, Lerche N, Moss B, Bellini W, McChesney M. 2000. Evaluation of recombinant vaccinia virus-measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276:202-213.
43. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM. 2003. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 21:3398-3405.
44. Vekemans J, Amedei A, Ota MO, D'Elios MM, Goetghebuer T, Ismaili J, Newport MJ, del Prete G, Goldman M, McAdam KP, Marchant A. 2001. Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur. J. Immunol. 31: 1531-1535.
45. Zhu Y, Fennelly G, Miller C, Tarara R, Saxe I, Bloom B, McChesney M. 1997. Recombinant Bacille Calmette-Guerin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia. J. Infect. Dis. 176:1445-1453.
46. Capozzo AV, Ramirez K, Polo JM, Ulmer J, Barry EM, Levine MM, Pasetti MF. 2006. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cellmediated immunity in the presence of maternal antibodies. J. Immunol. 176:5671-5681.
47. Zhang J, Silvestri N, Whitton JL, Hassett DE. 2002. Neonates mount robust and protective adult-like CD8(+)-T-cell responses to DNA vaccines. J. Virol. 76:11911-11919.
48. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, Williams KC, Schmitz JE, Reimann KA, Axthelm MK, Polack FP, Griffin DE, Letvin NL. 2003. Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J. Virol. 77:4396-4400.
49. Parker Fiebelkorn A, Redd SB, Gallagher K, Rota PA, Rota J, Bellini W, Seward J. 2010. Measles in the United States during the postelimination era. J. Infect. Dis. 202:1520-1528.